REACH/Galleri-Medicare Study

About GRAIL

GRAIL is a mission-driven company leveraging next-generation sequencing, population-scale clinical studies, and advanced machine learning to detect cancer early when it may be more treatable. Its clinical program has enrolled over 300,000 participants, and its Galleri test is at the forefront of the MCED category. The company is publicly traded and is focused on commercializing Galleri, expanding clinical utility evidence, and pursuing partnerships to integrate its test into healthcare systems globally.

Therapeutic Areas